Teva Pharmaceutical Industries Ltd. announced that it has completed the acquisition of Theramex, Merck KGaA’s European-based women’s health business.Â
Acquisition Provides Teva with a Strong Platform to Expand its Global Women’s Health Franchise
Theramex brings to Teva a broad portfolio of women’s health and gynecology products sold in over 50 countries, primarily France and Italy. Theramex’s pipeline includes NOMAC/E2, a new oral contraceptive based on natural estrogens, which has successfully completed phase III studies and was submitted for approval in Europe.
